Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug ...

Chimeric Antigen Receptor (CAR) T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of ...

Like the surface of the moon, new research published today in Cell finds the existence of craters on the surface of melanoma cells that serve as immune hubs, becoming major sites for tumor killing.

Please provide your email address to receive an email when new articles are posted on . Allogeneic cell therapies help overcome challenges of autologous products, such as manufacturing complexity and ...

LOUISVILLE, Ky. (WDRB) -- Researchers at the Indiana University School of Medicine are developing new ways to fight tumors and aggressive forms of cancer—such as triple-negative breast cancer, ...

MSK orthopedic surgeon Dr. Jonathan Forsberg examines Michelle Smith-Levitin’s leg at a follow-up appointment — a first-of-its-kind surgical implant saved her leg. The tennis court was Michelle ...

A New Jersey woman has been given a second chance at life, thanks to a new cancer therapy. Pamela Goldberger, 65, found out in 2023 that she had glioblastoma — a devastating diagnosis with an average ...

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing ...

At its July 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization in the European Union for Romvimza ...

Glioblastoma (GBM) is an aggressive and common brain cancer in adults with average life expectancies of 12–18 months after diagnosis and median survival rate for recurrent GBM ranging from 6–10 months ...

Patients with tenosynovial giant cell tumor can take some comfort in knowing that this rare type of tumor affecting joints won’t kill them. But that doesn’t make living with the disease easy. Merck ...

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of detailed positive results from Part 1 of the global Phase 3 MANEUVER ...